| Browse All

Pliant Therapeutics, Inc. (PLRX)

Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
1.28 USD -0.01 (-1.163%) ⇩ (April 21, 2026, 3:22 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 11:46 p.m. EDT

Pliant Therapeutics remains a high-risk speculative hold with no dividend support and deteriorating technicals, currently trading below its key moving averages despite a slight 1-week rebound. The recent board restructuring and option repricing to the current price floor suggest insider alignment with the bottom, but the absence of institutional accumulation in options (IV ~1%) and negative analyst forecasts (-1.6% predicted) point to a continued grind lower unless a specific catalyst triggers a liquidity event or pricing recovery.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.043799
AutoETS0.044381
AutoARIMA0.044586
AutoTheta0.113921

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 80%
H-stat 0.25
Ljung-Box p 0.000
Jarque-Bera p 0.207
Excess Kurtosis -0.07
Attribute Value
Sector Healthcare
Debt to Equity Ratio 16.062
Market Cap 78,941,192
Forward P/E -1.05
Beta 1.25
Website https://pliantrx.com

As of April 18, 2026, 11:46 p.m. EDT: Options flow shows absolute volume is extremely low across all expirations, with implied volatility near zero (0.50 - 1.66), indicating a lack of active speculation or liquidity at current lows. Positioning is sporadic and does not exhibit a clear directional bias; the 'Top OI' at the 7.5 strike for Oct 16 calls suggests detached, long-term speculative positioning by a single entity rather than market-wide conviction. Conversely, the 0.5 strike put on Oct 16 shows new flow but no open interest accumulation, suggesting transient activity. The data reflects a stale, low-volume environment where prices have continued to decline from the ATR (1.95) to current levels (1.33) without significant support at these lows.


Info Dump

Attribute Value
52 Week Change -0.13999999
Address1 331 Oyster Point Boulevard
All Time High 43.92
All Time Low 1.09
Ask 1.63
Ask Size 2
Average Daily Volume10 Day 512,680
Average Daily Volume3 Month 674,708
Average Volume 674,708
Average Volume10Days 512,680
Beta 1.245
Bid 0.9216
Bid Size 2
Book Value 2.949
City South San Francisco
Compensation As Of Epoch Date 1,735,603,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.275
Current Ratio 12.004
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 1.31
Day Low 1.26
Debt To Equity 16.062
Display Name Pliant Therapeutics
Earnings Timestamp 1,773,259,200
Earnings Timestamp End 1,778,184,000
Earnings Timestamp Start 1,778,184,000
Ebitda -148,376,992
Ebitda Margins 0.0
Enterprise To Ebitda 0.552
Enterprise Value -81,969,080
Eps Current Year -1.53445
Eps Forward -1.21718
Eps Trailing Twelve Months -2.43
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.2749
Fifty Day Average Change 0.000100016594
Fifty Day Average Change Percent 0.00007845055
Fifty Two Week Change Percent -13.999998
Fifty Two Week High 1.95
Fifty Two Week High Change -0.6750001
Fifty Two Week High Change Percent -0.3461539
Fifty Two Week Low 1.09
Fifty Two Week Low Change 0.18499994
Fifty Two Week Low Change Percent 0.16972472
Fifty Two Week Range 1.09 - 1.95
Financial Currency USD
First Trade Date Milliseconds 1,591,191,000,000
Float Shares 60,225,013
Forward Eps -1.21718
Forward P E -1.0475032
Free Cashflow -84,559,000
Full Exchange Name NasdaqGS
Full Time Employees 49
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.02379
Held Percent Institutions 0.77718
Implied Shares Outstanding 61,914,664
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,020-06-03
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Long Name Pliant Therapeutics, Inc.
Market us_market
Market Cap 78,941,192
Market State REGULAR
Max Age 86,400
Message Board Id finmb_325980525
Most Recent Quarter 1,767,139,200
Net Income To Common -149,344,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 79,250,769
Number Of Analyst Opinions 3
Open 1.28
Operating Cashflow -128,336,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 650 481 6770
Previous Close 1.29
Price Eps Current Year -0.8309166
Price Hint 4
Price To Book 0.43234995
Profit Margins 0.0
Quick Ratio 11.718
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.014999986
Regular Market Change Percent -1.1627896
Regular Market Day High 1.31
Regular Market Day Low 1.26
Regular Market Day Range 1.26 - 1.31
Regular Market Open 1.28
Regular Market Previous Close 1.29
Regular Market Price 1.275
Regular Market Time 1,776,799,351
Regular Market Volume 609,873
Return On Assets -0.30150998
Return On Equity -0.61549
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 61,914,664
Shares Percent Shares Out 0.065
Shares Short 4,025,957
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 3,785,164
Short Name Pliant Therapeutics, Inc.
Short Percent Of Float 0.066599995
Short Ratio 7.56
Source Interval 15
State CA
Symbol PLRX
Target High Price 3.0
Target Low Price 2.0
Target Mean Price 2.66667
Target Median Price 3.0
Total Cash 190,944,000
Total Cash Per Share 3.084
Total Debt 29,105,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.43
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.427575
Two Hundred Day Average Change -0.15257502
Two Hundred Day Average Change Percent -0.10687706
Type Disp Equity
Volume 609,873
Website https://pliantrx.com
Zip 94,080